Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Peripheral Vasodilator Drugs Market Size Shifted, And What Is the Outlook Through 2034?
The market for peripheral vasodilator drugs has seen remarkable growth in recent times. The trend is projected to continue, with the market value set to rise from $6.27 billion in 2024 to $6.61 billion in 2025, representing a compound annual growth rate (CAGR) of 5.3%. Factors propelling this growth during the past period include a transition to less invasive surgical methods, an increased demand for minimally invasive structural heart devices, the commitment to continuous training and education of healthcare professionals, an increase in healthcare spending, and a surge in patient preference for non-surgical or minimally invasive treatment alternatives.
The market for peripheral vasodilator drugs is anticipated to experience robust expansion in the upcoming years, reaching a value of $8.18 billion in 2029 at a CAGR of 5.5%. This surge in the projected period can be credited to various factors such as the rising elderly population, heightened consciousness about cardiac health, the execution of health screening programs, beneficial monetary compensation policies for structural cardiac procedures, and prompt regulatory sanctioning for the introduction of new structural heart apparatus. The forecast period is also predicted to witness major trends such as heightened collaborations, real-world proofs, gene therapy, preventive measures, and value-driven healthcare.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16508&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Peripheral Vasodilator Drugs Market?
The peripheral vasodilator drug market is anticipated to expand due to the rising number of cardiovascular diseases. These disorders, affect the heart and blood vessels and are often due to atherosclerosis, which can lead to heart attacks, strokes, hypertension, and heart failure. The onset of these diseases is mostly due to factors like sedentary lifestyles, unhealthy diets, aging populations, increasing obesity rates and associated health conditions such as diabetes and hypertension. Peripheral vasodilators play a crucial role in cardiovascular diseases, as they enhance blood flow, lower blood pressure, lessen the workload of the heart, and ease symptoms of ailments like peripheral arterial disease. For example, the Australian Institute of Health and Welfare reported in June 2024 that doctor-certified deaths due to coronary heart disease (CHD) had surged to 14,100 in 2021 and then to 14,900 in 2022. As such, the escalating prevalence of cardiovascular diseases is fueling the growth of the peripheral vasodilator drug market.
Which Key Market Segments Comprise the Peripheral Vasodilator Drugs Market and Drive Its Revenue Growth?
The peripheral vasodilator drugs market covered in this report is segmented –
1) By Drug Type: Calcium Channel Blockers, Direct-Acting Vasodilators, Alpha-Adrenergic Blockers, Potassium Channel Activators, Nitrates, Other Types
2) By Indication: Hypertension, Angina, Heart Failure, Other Indications
3) By Application: Hospital, Retail Pharmacies, Other Applications
Subsegments:
1) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
2) By Direct-Acting Vasodilators: Hydralazine, Minoxidil, Nitroprusside
3) By Alpha-Adrenergic Blockers: Prazosin, Doxazosin, Terazosin
4) By Potassium Channel Activators: Nicorandil, Diazoxide
5) By Nitrates: Nitroglycerin, Isosorbide Dinitrate, Isosorbide Mononitrate
6) By Other Types: Phosphodiesterase Inhibitors, Endothelin Receptor Antagonists
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=16508&type=smp
Which Areas Are Leading Regions in the Peripheral Vasodilator Drugs Market Expansion Across the Globe?
North America was the largest region in the peripheral vasodilator drugs market in 2024. The regions covered in the peripheral vasodilator drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in thePeripheral Vasodilator Drugs Market Over the Coming Years?
Leading firms in the peripheral vasodilator drugs market are concentrating on the advancement of triple-drug combination therapies to enhance treatment results and broaden their cardiovascular therapeutics market share. The triple-drug combination therapy is an antihypertensive fixed-dose combination (FDC) designed for patients who have not shown satisfactory blood pressure management with two-drug therapies or cannot endure diuretic-based combinations. Specifically, Ajanta Pharma Limited, an Indian pharmaceutical company specializing in cardiology, launched Met XL AMT in August 2023. This innovative triple-drug combination aims to control hypertension in Indian patients. It is an FDC of three antihypertensive agents, namely Telmisartan, Amlodipine, and Metoprolol, which jointly function to reduce blood pressure by relaxing blood vessels, an attribute of peripheral vasodilators. The DCGI has specifically approved the drug for managing intractable hypertension as well as stable coronary artery disease. This makes it the world’s premier fixed-dose combination (FDC) of metoprolol succinate (extended-release) 50 mg, amlodipine 5 mg, and telmisartan 40 mg.
View the full report here:
https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report
How Is the Peripheral Vasodilator Drugs Market Conceptually Defined?
Peripheral vasodilator drugs refer to medications that primarily act on blood vessels outside of the heart and brain, specifically targeting the peripheral circulation. These drugs are used to widen (dilate) blood vessels, thereby reducing resistance to blood flow and lowering blood pressure.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16508
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model